Carregando...
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma (HCC). However, the benefit...
Na minha lista:
| Publicado no: | Int J Med Sci |
|---|---|
| Principais autores: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ivyspring International Publisher
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7893555/ https://ncbi.nlm.nih.gov/pubmed/33628103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijms.51256 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|